Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Astellas, Amgen Clinch Strategic Alliance on 5 Products; JV to Begin Operations in October
May 30, 2013
- Eisai Launches Antiepileptic Treatment Inovelon
May 30, 2013
- Nippon Shinyaku Launches Regtect for Supporting Maintenance of Abstinence in Alcohol-Dependent Patients
May 30, 2013
- Ex-Novartis Employee Attended Key Panel Meetings for Diovan Trial
May 29, 2013
- MTPC Files NDA for SGLT-2 Inhibitor Canagliflozin in Japan
May 29, 2013
- Sales of 27 JPMA Member Companies Up 2.6%, First Rise in Two Years Thanks to Overseas Sales Growth
May 28, 2013
- Kyorin Aims for Pentasa Sales Increase in FY2013 with Suppository Formulation: President Yamashita
May 28, 2013
- NPhA Member Companies Will Strive to Reach Price Agreements with Wholesalers by September: Chairman Nakamura
May 28, 2013
- Hisamitsu, Asahi Kasei to Launch Overactive Bladder Treatment Neoxy Tape in June
May 28, 2013
- Astellas Files NDA for Prostate Cancer Treatment Enzalutamide in Japan
May 28, 2013
- “No Indication” of Data Manipulation in Diovan Studies: Novartis
May 27, 2013
- Bayer Launches Anticancer Treatment Stivarga
May 27, 2013
- 2012 Earnings: Foreign Pharmas’ Japan Units Underperform Market Growth, Operating Profit Down 21%
May 27, 2013
- Kyowa Kirin to Launch DPP-4 Inhibitor Onglyza in July Without Concurrent Use Restrictions
May 27, 2013
- OPF to Exclusively Market 3 Plasma Volume Expanders in Japan
May 24, 2013
- Daiichi Sankyo: Ranbaxy Former Shareholders Hid Critical Information
May 24, 2013
- Japan’s 1st Western Herbal Medicine Antistax to Hit Shelves in June: SSP
May 24, 2013
- Vital KSK HD Reports Single-Product, Single-Price Agreements Reached with Nearly 100% of Customers by End of March
May 24, 2013
- Pfizer Discontinues PIII Study of Inotuzumab Ozogamicin for NHL
May 24, 2013
- About 80% of Drug Makers Have Introduced Web Seminars; Cost-savings, Increased Sales Reported
May 24, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…